JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB323150

Recombinant Human MAVS Protein Standard

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Human MAVS Protein Standard is a Human Fragment protein, expressed in HEK 293 cells, with >80%, suitable for sELISA, SDS-PAGE.

View Alternative Names

IPS1, KIAA1271, VISA, Mitochondrial antiviral-signaling protein, MAVS, CARD adapter inducing interferon beta, Interferon beta promoter stimulator protein 1, Putative NF-kappa-B-activating protein 031N, Virus-induced-signaling adapter, Cardif, IPS-1

2 Images
Sandwich ELISA - Recombinant Human MAVS Protein Standard (AB323150)
  • sELISA

Supplier Data

Sandwich ELISA - Recombinant Human MAVS Protein Standard (AB323150)

Sandwich ELISA with the capture antibody dilution at 2 µg/mL and detector antibody dilution at 0.5 µg/mL.

SDS-PAGE - Recombinant Human MAVS Protein Standard (AB323150)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human MAVS Protein Standard (AB323150)

SDS-PAGE analysis of ab323150 under reducing conditions for 2ug protein.

Key facts

Purity

>80% SDS-PAGE

Expression system

HEK 293 cells

Tags

Tag free

Applications

sELISA, SDS-PAGE

applications

Biologically active

No

Accession

Q7Z434

Animal free

Yes

Carrier free

No

Species

Human

Storage buffer

pH: 7.3 - 7.5 Constituents: 2.922% Sodium chloride, 0.64107% disodium;hydrogen phosphate;dodecahydrate, 0.02858% Potassium phosphate monobasic

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

While the standard is the same as the one provided in the corresponding SimpleStep ELISA Kit, it cannot be treated as the consumable provided with our SimpleStep ELISA Kit due to differences in its concentration calibration.Abcam guarantee that this protein standard is suitable for use in a sandwich ELISA. Individual results may vary due to differences in technique, laboratory equipment, buffers, and other experimental factors. The detection range provided for this protein standard is based on initial sandwich ELISA validation data.The protein concentration is the concentration after validation on our sandwich ELISA platform. This Standard protein is guaranteed to work with our Capture and Detector antibodies in sELISA. Please contact our Scientific Support team to know which antibody pair is suitable for this protein.

Sequence info

[{"sequence":null,"proteinLength":"Fragment","predictedMolecularWeight":"12 kDa","actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q7Z434","tags":[]}]

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Specifications

Form

Liquid

General info

Function

Adapter required for innate immune defense against viruses (PubMed : 16125763, PubMed : 16127453, PubMed : 16153868, PubMed : 16177806, PubMed : 19631370, PubMed : 20127681, PubMed : 20451243, PubMed : 21170385, PubMed : 23087404, PubMed : 27992402, PubMed : 33139700, PubMed : 37582970). Acts downstream of DHX33, RIGI and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFNB and RANTES (CCL5) (PubMed : 16125763, PubMed : 16127453, PubMed : 16153868, PubMed : 16177806, PubMed : 19631370, PubMed : 20127681, PubMed : 20451243, PubMed : 20628368, PubMed : 21170385, PubMed : 23087404, PubMed : 25636800, PubMed : 27736772, PubMed : 33110251). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state (PubMed : 20451243). Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response (PubMed : 20451243). May activate the same pathways following detection of extracellular dsRNA by TLR3 (PubMed : 16153868). May protect cells from apoptosis (PubMed : 16125763). Involved in NLRP3 inflammasome activation by mediating NLRP3 recruitment to mitochondria (PubMed : 23582325).

Post-translational modifications

Following activation, phosphorylated by TBK1 at Ser-442 in the pLxIS motif (PubMed:25636800, PubMed:27302953). The phosphorylated pLxIS motif constitutes an IRF3-binding motif, leading to recruitment of the transcription factor IRF3 to induce type-I interferons and other cytokines (PubMed:25636800).. Ubiquitinated (PubMed:19881509, PubMed:23087404, PubMed:25636800, PubMed:38016475). Undergoes 'Lys-48'-linked polyubiquitination catalyzed by ITCH; ITCH-dependent polyubiquitination is mediated by the interaction with PCBP2 and leads to MAVS/IPS1 proteasomal degradation (PubMed:19881509). Ubiquitinated by RNF125, leading to its degradation by the proteasome (PubMed:17460044). Undergoes 'Lys-48'-linked ubiquitination catalyzed by SMURF1 (PubMed:23087404). Ubiquitinated via 'Lys-63'-linked ubiquitination at Lys-10, Lys-311 and Lys-461 by UBE2N and TRIM31, promoting MAVS polymerization and formation of three-stranded helical filaments on mitochondria (PubMed:27992402, PubMed:37582970). Undergoes 'Lys-63'-linked ubiquitination leading to enhanced interaction between MAVS and TRAF2 (PubMed:34880843). Undergoes 'Lys-27'-linked ubiquitination by TRIM21 leading to enhanced interaction between MAVS and TBK1 (PubMed:29743353, PubMed:36943869). Deubiquitinated by USP10 leading to attenuation of RIGI-mediated MAVS aggregation and production of type I interferon (PubMed:37582970). Undergoes 'Lys-48'-linked polyubiquitination catalyzed by RNF115 leading to its degradation (PubMed:33139700).. Palmitoylated by ZHDDC4. Palmitoylation promotes MAVS stabilization and activation by inhibiting 'Lys-48'- but facilitating 'Lys-63'-linked ubiquitination.. Proteolytically cleaved by apoptotic caspases during apoptosis, leading to its inactivation (PubMed:30878284). Cleavage by CASP3 during virus-induced apoptosis inactivates it, preventing cytokine overproduction (PubMed:30878284).. (Microbial infection) Cleaved and degraded by hepatitis A virus (HAV) protein 3ABC allowing the virus to disrupt the activation of host IRF3 through the MDA5 pathway.. (Microbial infection) Cleaved by the protease 2A of coxsackievirus B3, poliovirus and enterovirus 71 allowing the virus to disrupt the host type I interferon production.. (Microbial infection) Cleaved by Seneca Valley virus protease 3C allowing the virus to suppress interferon type-I production.. (Microbial infection) Cleaved by HCV protease NS3/4A, thereby preventing the establishment of an antiviral state.. (Microbial infection) UFMylated by ULF1 in association with Epstein-Barr virus BILF1; leading to MAVS routing to the lysosome.

Subcellular localisation

Mitochondrion outer membrane

Product protocols

Target data

Adapter required for innate immune defense against viruses (PubMed : 16125763, PubMed : 16127453, PubMed : 16153868, PubMed : 16177806, PubMed : 19631370, PubMed : 20127681, PubMed : 20451243, PubMed : 21170385, PubMed : 23087404, PubMed : 27992402, PubMed : 33139700, PubMed : 37582970). Acts downstream of DHX33, RIGI and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFNB and RANTES (CCL5) (PubMed : 16125763, PubMed : 16127453, PubMed : 16153868, PubMed : 16177806, PubMed : 19631370, PubMed : 20127681, PubMed : 20451243, PubMed : 20628368, PubMed : 21170385, PubMed : 23087404, PubMed : 25636800, PubMed : 27736772, PubMed : 33110251). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state (PubMed : 20451243). Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response (PubMed : 20451243). May activate the same pathways following detection of extracellular dsRNA by TLR3 (PubMed : 16153868). May protect cells from apoptosis (PubMed : 16125763). Involved in NLRP3 inflammasome activation by mediating NLRP3 recruitment to mitochondria (PubMed : 23582325).
See full target information MAVS

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com